| Literature DB >> 32942596 |
Waleed El-Kazzaz1, Lobna Metwally2,3, Reham Yahia4, Najwa Al-Harbi5, Ayat El-Taher6, Helal F Hetta7,8.
Abstract
Acinetobacter spp. has gained fame from their ability to resist difficult conditions and their constant development of antimicrobial resistance. This study aimed to investigate the prevalence, susceptibility testing, OXA carbapenemase-encoding genes, and RAPD-genotyping of multidrug resistant Acinetobacter baumannii incriminated in hidden community-acquired infections in Egypt. The antimicrobial susceptibility testing was assessed phenotypically using Kirby-Bauer disk diffusion method. Also, Modified-Hodge test (MHT) was carried out to detect the carbapenemases production. Multiplex-PCR was used to detect the carbapenemase-encoding genes. Furthermore, the genetic relationship among the isolated strains was investigated using RAPD fingerprinting. The bacteriological examination revealed that, out of 200 Gram-negative non-fermentative isolates, 44 (22%) were identified phenotypically and biochemically as Acinetobacter spp. and 23 (11.5%) were molecularly confirmed as A.baumannii. The retrieved A.baumannii strains were isolated from urine (69%), sputum (22%), and cerebrospinal fluid (csf) (9%). The isolated A. baumannii strains exhibited multidrug resistance and the production rates of carbapenemases were 56.5, 60.9, and 78.3% with meropenem, imipenem, and ertapenem disks, respectively. The blaOXA-24-like genes were the most predominant among the tested strains (65.2%), followed by blaOXA-23 (30.4%) and blaOXA-58 (17.4%), in addition, the examined strains are harbored IMP, VIM, and NDM genes with prevalence of 60.9, 43.5, and 13%, respectively, while KPC and GES genes were not detected. RAPD-PCR revealed that the examined strains are clustered into 11 different genotypes at ≥90% similarity. Briefly, to the best of our knowledge, this study is the first report concerning community-associated A. baumannii infections in Egypt. The high prevalence of hidden multidrug-resistant (MDR) and extensively drug-resistant (XDR) A.baumannii strains associated with non-hospitalized patients raises an alarm for healthcare authorities to set strict standards to control the spread of such pathogens with high rates of morbidity and mortality.Entities:
Keywords: Acinetobacter baumannii; MDR; RAPD-genotyping; antibiogram; carbapenemase encoding genes
Year: 2020 PMID: 32942596 PMCID: PMC7558960 DOI: 10.3390/antibiotics9090603
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Distribution of Gram-negative non-fermentative isolates according to sample source and patient gender (n = 200).
| Sample Origin | Gender | Urine | Sputum | Pus | Blood | Wound | CSF * | Total | Collecting Lab. | |
|---|---|---|---|---|---|---|---|---|---|---|
| Strain | n (%) | |||||||||
|
| Male | 36 | 18 | 6 | 10 | 21 | 3 | 94 (47) | 100% | |
| 21 | 13 | 4 | 8 | 14 | 2 | 62 (31) | ||||
| 57 | 31 | 10 | 18 | 35 | 5 | 156 (78) | ||||
|
| Male | 0 | 1 | - | - | - | 1 | 2 (1) | unidentified | |
| 16 | 4 | - | - | - | 1 | 21 (10.5) | ||||
| 16 | 5 | - | - | - | 2 | 23 (11.5) | ||||
|
| Male | 2 | 3 | - | 1 | - | - | 6 (3) | unidentified | |
| 1 | 0 | - | 0 | - | - | 1 (0.5) | ||||
| 3 | 3 | - | 1 | - | - | 7 (3.5) | ||||
|
| Male | - | - | 1 | 1 | - | - | 2 (1) | unidentified | |
| - | - | 0 | 0 | - | - | 0 | ||||
| - | - | 1 | 1 | - | - | 2 (1) | ||||
|
| Male | 0 | 1 | 1 | - | 2 | - | 4 (2) | unidentified | |
| 1 | 0 | 0 | - | 1 | - | 2 (1) | ||||
| 1 | 1 | 1 | - | 3 | - | 6 (3) | ||||
|
| Male | - | 0 | - | - | 1 | - | 1 (0.5) | unidentified | |
| - | 1 | - | - | 1 | - | 2 (1) | ||||
| - | 1 | - | - | 2 | - | 3 (1.5) | ||||
|
| Male | - | - | - | 0 | - | 1 | 1 (0.5) | unidentified | |
| - | - | - | 2 | - | 0 | 2 (1) | ||||
| - | - | - | 2 | - | 1 | 3 (1.5) | ||||
| Total | Male | 38 | 23 | 8 | 12 | 24 | 5 | 110 (55) | ||
| 39 | 18 | 4 | 10 | 16 | 3 | 90 (45) | ||||
| 77 | 41 | 12 | 22 | 40 | 8 | 200 | ||||
* cerebrospinal fluid.
Distribution of A. baumannii isolates according to sample source.
| Variables | Sample Origin | Sign | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Urine | Sputum | CSF | Total | |||||||
| n | % | n | % | n | % | n | ||||
| Gender | Male | 0 | 0.0 | 1 | 50 | 1 | 50 | 2 | 0.009 * | |
| Female | 16 | 76.2 | 4 | 19.0 | 1 | 4.8 | 21 | |||
| Total | 16 | 69.6 | 5 | 21.7 | 2 | 8.7 | 23 | |||
| Age | Male (mean ± SD) | 0.0 | 18.0 ± 19.02 | 52.0 ± 19.21 | 35.0 ± 13.58 | 0.049 * | ||||
| Female (mean ± SD) | 41.5 ± 4.80 | 44.0 ± 9.60 | 5.0 ± 19.21 | 30.17 ± 7.34 | ||||||
| Total (mean ± SD) | 41.5 ± 16.23 | 38.8 ± 28.40 | 28.5 ± 33.20 | 39.8 ± 19.90 | 0.695 ns | |||||
| Age groups | 0–15 years | 0 | 0.0 | 1 | 50.0 | 1 | 50.0 | 2 | 0.333 ns | |
| 16–30 years | 7 | 87.5 | 1 | 12.5 | 0 | 0.0 | 8 | |||
| 31–55 years | 4 | 66.7 | 1 | 16.7 | 1 | 16.7 | 6 | |||
| >56 years | 5 | 71.4 | 2 | 28.6 | 0 | 0.0 | 7 | |||
| Total | 16 | 69.6 | 5 | 21.7 | 2 | 8.7 | 23 | |||
* significant at p < 0.05; ns, non-significant at p > 0.05.
Figure 1Random Amplification of Polymorphic DNA (RAPD) type, strain, source, carbapenemases, antimicrobial susceptibility, and MHT test of the 23 A. baumannii isolates. Individual isolates showing hierarchical clustering of isolates and factors. Binary factor (carbapenemase genes) indicated by presence (+) and absence (-); however, ordinal factor (antibiotics) indicating resistance by orange color, intermediate (yellow), and sensitive (green). Abbreviations: tobramycin (TOB), gentamycin (CN), amikacin (AK), norfloxacin (NOR), levofloxacin (LEV), ciprofloxacin (CIP), nalidixic acid (NA), ampicillin (AMP), piperacillin (PRL), amoxicillin/clavulanic acid (ATM), ceftazidime (CAZ), cefepime (FEP), cefotaxime (CTX), meropenem (MEM), imipenem (IPM), doripenem (DO), ertapenem (ETP), colistin (CT), and polymyxin B (PB).
Antimicrobial resistance profiles of A. baumannii.
| Antimicrobial | Resistance ( | Sign. | ||
|---|---|---|---|---|
| S | R | I | ||
| Tobramycin | (8) 34.8% | (15) 65.2% | 0 | 0.144 ns |
| Gentamycin | (5) 21.7% | (17) 73.9% | (1) 4.3% | <0.001 * |
| Amikacin | (11) 47.8% | (12) 52.2% | 0 | 0.835 ns |
| Aztreonam | (3) 13% | (20) 87% | 0 | <0.001 * |
| Norfloxacin | (7) 30.4% | (16) 69.6% | 0 | 0.061 ns |
| Levofloxacin | (6) 26.1% | (15) 65.2% | (2) 8.7% | 0.003 * |
| Ofloxacin | (8) 34.8% | (14) 60.9% | (1) 4.3% | 0.0004 * |
| Ciprofloxacin | (7) 30.4% | (16) 69.6% | 0 | 0.061 ns |
| Nalidixic acid | 0 | (23) 100% | 0 | <0.001 * |
| Piperacillin/tazobactam | (3) 13% | (19) 82.6% | (3) 13% | <0.001 * |
| Oxacillin | 0 | (23) 100% | 0 | <0.001 * |
| Amoxicillin/clavulanic acid | 0 | (23) 100% | 0 | <0.001 * |
| Ceftazidime | (2) 8.7% | (20) 87% | (1) 4.3% | <0.001 * |
| Cefotaxime | (1) 4.3% | (21) 91.3% | (1) 4.3% | <0.001 * |
| Cefepime | (9) 39.1% | (13) 56.5% | (1) 4.3% | 0.008 * |
| Meropenem | (8) 34.8% | (12) 52.2% | (3) 13% | 0.070 ns |
| Imipenem | (10) 39.1% | (11) 47.8% | (2) 8.7% | <0.001 * |
| Ertapenem | (3) 13% | (20) 87% | 0 | <0.001 * |
| Doripenem | (5) 21.7% | (17) 73.9% | (1) 4.3% | <0.001 * |
| Colistin | (17) 73.9% | (4) 17.4% | (2) 8.7% | <0.001 * |
| Polymyxin B | (19) 82.6% | (4) 17.4% | 0 | 0.002 * |
* significant at p < 0.05; ns, non-significant at p > 0.05.
Figure 2Multiplex PCR identification of OXA carbapenemase gene families in A. baumannii under investigation. A, B, C, and D mark for blaOXA-23 (1058 bp), blaOXA-58 (599 bp), blaOXA-51 (353 bp), and blaOXA-24 (246 bp) fragments, respectively. (M) indicates 100 bp Marker from Genetex, A. baumannii strains in the study from lane 1 to 23, and lane 24 represent blaOXA-23 positive control strain.
Sequence, amplicon size and annealing temperature of oligos used in the study.
| Oligo | Sequence (5′→3′) | Amplicon Size (bp) | Annealing Tmp (°C) | Reference |
|---|---|---|---|---|
| (16-23S ITS) P-1512F | GTCGTAACAAGGTAGCCGTA | 607 | 60 | [ |
| (16-23S ITS) P-6R | GGGTTC/TCCCCA/GTTCRGAAAT | |||
| CTAATAATTGATCTACTCAAG | 975 | 48 | [ | |
| CCAGTGGATGGATGGATAGATTATC | ||||
| TAATGCTTTGATCGGCCTTG | 353 | 52 | [ | |
| TGGATTGCACTTCATCTTGG | ||||
| GATGTGTCATAGTATTCGTCGT | 1058 | [ | ||
| TCACAACAACTAAAAGCACTGT | ||||
| GGTTAGTTGGCCCCCTAAAA | 246 | [ | ||
| AGTTGAGCGAAAAGGGGATT | ||||
| AAGTATTGGGGCTTGTGCTG | 599 | [ | ||
| CCCCTCTGCGCTCTACATAC | ||||
| ( | GGAATAGAGTGGCTTAAYTCTC | 232 | 52 | [ |
| ( | GATGGTGTTTGGTCGCATA | 390 | ||
| ( | GGTTTGGCGATCTGGTTTTC | 621 | ||
| ( | CGTCTAGTTCTGCTGTCTTG | 798 | ||
| ( | ATGCGCTTCATTCACGCAC | 863 | 55 | [ |
| OPM-01 (P1) | GTTGGTGGCT | Variable | 40 | Eurofins Kit |
| OPM-07 (P2) | CCGTGACTCA | |||
| OPM-09 (P3) | GTCTTGCGGA | |||
| OPQ-06 (P4) | GAGCGCCTTG | |||
| OPQ-08 (P5) | CTCCAGCGGA | |||
| OPM-03 (P6) | GGGGGATGAG | |||
| OPQ-02 (P7) | TCTGTCGGTC | |||
| OPM-05 (P8) | GGGAACGTGT | |||
| OPQ-04 (P9) | AGTGCGCTGA | |||
| OPQ-10 (P10) | TGTGCCCGAA |
Figure 3RAPD genotyping of the strains. (a) Combined RAPD patterns of 23 clinical Acinetobacter isolates obtained after electrophoresis of the PCRs with five different primers individually. For each primer, five RAPD gels were combined into one image. (b) RAPD dendrogram was constructed with GelJ cluster analysis software by Unweighted Pair Group Method with Arithmetic Mean UPGMA). Percentages of similarity and primers used as presented in Table 3 on the top line of the dendrogram. RAPD type and strain code as in Table 3 and strain numbers as presented in Figure 3a appear on the right (between parenthesis).